Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-038711
Filing Date
2025-04-24
Accepted
2025-04-24 16:43:44
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm252466d3_defa14a.htm DEFA14A 12006
2 GRAPHIC tm252466d3_defa14aimg001.jpg GRAPHIC 179619
3 GRAPHIC tm252466d3_defa14aimg002.jpg GRAPHIC 107618
  Complete submission text file 0001104659-25-038711.txt   409294
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37939 | Film No.: 25868252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)